Survivin expression starts before hepatocellular cancer development in the liver of chronic hepatitis B patients: a pilot, cross-sectional study

Muhammet Yener Akpinar1, Gulcin Guler Simsek2, Evrim Kahramanoglu Aksoy1, Ferda Pirincci Sapmaz1, Selen Kantarci3, Metin Uzman1, Yasar Nazligul1

1Gastroenterology Department, Kecioren Training and Research Hospital, Ankara, Turkey
2Pathology Department Kecioren Training and Research Hospital, Ankara, Turkey
3Internal Medicine Department, Kecioren Training and Research Hospital, Ankara, Turkey

Gastroenterology Rev
DOI: https://doi.org/10.5114/pg.2019.87081

Key words: apoptosis, chronic hepatitis B, surviving.

Address for correspondence: Muhammet Yener Akpinar, Gastroenterology Department, Kecioren Training and Research Hospital, Ankara, Turkey, phone: +90 5062047839, e-mail: muhammet.yener@gmail.com

Abstract

Introduction: Survivin expression is well known feature of hepatocellular carcinoma (HCC); however, there is no information about survivin expression in chronic hepatitis B (CHB).

Aim: Investigating survivin expression in the liver of CHB patients.

Material and methods: This is a single-centre, cross-sectional study. Seventy-five CHB patients and eight control patients were enrolled into the study between 2008 and 2018. Immunohistochemical study was performed by using anti-survivin antibody to evaluate survivin immunoreactivity.

Results: Survivin immunoreactivity was significantly higher in CHB patients compared to controls ($p = 0.008$). Also, the degree of survivin immunoreactivity was significantly higher in CHB patients ($p = 0.027$). Between the anti-survivin-positive and anti-survivin-negative groups, baseline laboratory parameters and initial pathology features were not significantly different.

Conclusions: This is the first study evaluating survivin expression in CHB patients. Understanding the possible relationship between survivin expression and HCC development in this population can promote new studies in terms of new therapies and treatment timing.

Introduction

Chronic hepatitis B (CHB) is still an important public health problem; worldwide 330 million people are infected with this virus [1, 2]. Its clinical course is not homogenous in all patients; some individuals carry this virus throughout their life, but others develop cirrhosis and hepatocellular carcinoma (HCC). Current treatment options can only stop disease progression, rather than viral eradication. As noted above, HCC is an important consequence of hepatitis B virus (HBV); it develops in HBV-related CHB and also in HBV-related cirrhosis [3]. Also, HCC can be detected in inactive HBV carriers, the incidence of HCC in this group of patients is less than 0.3% per year. It is important to recognise HCC in its early stage in terms of improved survival with effective HCC treatments [4].

Survivin is an anti-apoptotic protein, which was first discovered in 1997 [5]. Subsequently, studies disclosed its structure and function. Survivin, a 142 amino acid containing protein, is a member of the inhibitor apoptosis protein (IAP) family. Its gene is located at 17q25 and is expressed in the G2/M phase [6]. Some protein members of IAP family expressed in both embryonic and terminally differentiated tissues [7, 8]. It was demonstrated by using northern hybridisation that adult liver, spleen, pancreas, kidney, and other visceral organs did not express survivin [9]. Survivin expression is undetectable in all terminally differentiated tissues except thymus, testis, vascular endothelial cells, and CD34+ stem cells. Nowadays, it is well known that this protein plays a major role in many malignancies, including gastric cancer, lung cancer, colon cancer, and ovarian cancer.
Survivin expression is associated with advanced stage and poor differentiation in malignancies [11]. In the literature, most of the studies investigate survivin in HCC as a potential stimulator of malignancy. Nevertheless few studies investigate survivin expression in CHB. In 2000, Ito et al. demonstrated that survivin promotes tumoural cell proliferation in HCC [12]. After that many studies revealed survivin expression in HCC. In the view of this information, we hypothesised that survivin expression can start in the liver of CHB patients before the cirrhotic situation and HCC.

Aim

In this study our aim is to investigate survivin expression in the liver of CHB patients.

Material and methods

Study design and tissue sampling

This is a single-centre retrospective cross-sectional study. Seventy-five CHB patients and eight control patients were enrolled into the study between 2008 and 2018. Liver biopsy was performed in all CHB patients for documentation of liver necro-inflammatory activity and fibrosis before initial medical treatment. The control group comprised cholecystectomy materials with intact liver tissue without any proof of acute and/or chronic inflammatory liver disease. Eight laparoscopic cholecystectomy patients fulfilled these criteria. Liver biopsies were processed in an automated tissue processor and placed in tissue paraffin blocks. Hae-matoxylin and eosin (H&E)-stained slides were prepared for biopsy samples. The biopsy specimen was considered sufficient if it comprised 6–8 portal spaces. All liver biopsy specimens were evaluated by the same pathologist, who was experienced in liver pathology and blinded to the clinical data of the patients. In CHB patients, liver pathology was performed with the Ishak scoring system. According to modified Hepatitis Activity Index (HAI), patients were subdivided into three groups based on their scores: minimal HAI with 1–3 points, mild HAI with 4–6 points, and moderate HAI with 9–12 points. Bridging fibrosis describes a fibrosis score of 3 or 4.

Immunohistochemical staining and immunostaining evaluation

Immunohistochemical staining of sections from the liver tissue samples was performed using a Ventana BenchMark GX (Roche Diagnostics, Basel, Switzerland). In brief, after deparaffinisation using EZ-Prep (Roche Diagnostics) and antigen retrieval using Cell Conditioning 1 buffer at 95°C for 32 min, sections were incubated with primary antibodies. The primary antibodies were anti-survivin (cat. no. ABP54792, polyclonal, dilution 1 : 200; R&D systems, California, USA). Immunoreactivity was considered based on nuclear staining and by counting 100 hepatocytes under a high-power field. The severity of immunoreactivity was assigned by percentage as positive cell number: Grade 0: no staining (Figure 1), Grade 1: 1–20% (Figure 2) and Grade 2: > 20% staining (Figure 3).

Ethical considerations

The study was approved by an Internal Review Board on 14 February 2018.

Statistical analysis

The normality of distribution of continuous variables was tested by Shapiro-Wilk test. Mann-Whitney U and Kruskal-Wallis tests were used for comparison of non-normal numerical variables between two or three independent groups, respectively. Dunn’s multiple comparison test was applied when the Kruskal-Wallis test
result was significant. The χ² test was applied to investigate the relationship between two categorical variables, and Spearman rank correlation coefficients were used to assess the relation between non-normal numerical variables. Statistical analysis was performed with SPSS for Windows version 24.0, and a p-value < 0.05 was accepted as statistically significant.

**Results**

A total of 75 CHB patients were enrolled into the study. Mean age was 45.95 ±10.13 years, 36 patients were female, and 39 patients were male. Between the groups, there is no statistically different according to sex and age (p = 0.436 and p = 0.350, respectively). Most of the patients (n = 70) were HbeAg-/AntiHbe+, and the rest were HbeAg+. Mean levels of initial laboratory parameters were 60.30 ±80.88 for alanine aminotransferase (ALT), 45.02 ±65.73 for aspartate aminotransferase (AST), 2.03 ±1.44 for α-fetoprotein (AFP), and 2292.2 ±2146.45 for HbsAg. In standard pathological examination, according to HAI, most of our patients were mild. The mean HAI score was 4.87 ±2.04. Also, fibrosis was generally mild and, in some cases, moderate, with a mean score of 1.12 ±0.96. Demographic characteristics, baseline laboratory parameters, and initial pathological findings are listed in Tables I and II.

Survivin immunoreactivity was observed in 46 patients in CHB; nevertheless, pathology preparations were not stained by anti-survivin antibody in 29 patients. In 46 patients, immunoreactivity was observed as grade 2 in 14 patients and grade 1 in 32 patients. On the other hand, only 1 patient’s preparation showed immunoreactivity in the control group. Between patients and control groups, the presence of survivin immunoreactivity and severity was significantly higher in CHB patients compared to controls (p = 0.008 and p = 0.028, respectively) (Table III).

In CHB patients, we compared HAI, the presence of fibrosis, and bridging fibrosis between patients in whom survivin immunoreactivity was positive and those in whom it was negative. There was no significant difference of these parameters between two groups. In addition, we also evaluated HAI, the presence of fibrosis, and bridging fibrosis according to the severity of survivin immunoreactivity. HAI and the presence of fibrosis were not significantly different between the grade 1 and grade 2 groups. However, bridging fibrosis was significantly higher in the grade-1 group compared to others (p = 0.027) (Tables IV, V). We also compared baseline laboratory parameters such as ALT, AST, AFP, HbsAg, and HBV-DNA between anti-survivin stain-positive and anti-survivin stain-negative groups. According to this comparison, no significant difference was found between these parameters (p = 0.011 for ALT, p = 0.957 for AST, p = 0.327 for AFP, p = 0.101 for HbsAg, and p = 0.948 for HBV-DNA).

In this study we also evaluated the correlation between survivin immunoreactivity, baseline laboratory parameters and initial pathology parameters. When we investigate the correlation between the severity of survivin immunoreactivity and laboratory parameters such as AFP, HBV-DNA, HbsAg, ALT, and AST, we did not find a significant correlation between these parameters.
Table II. Mean values of baseline laboratory parameters and initial pathology features of patients

| Variables                  | N   | Mean  | Std. deviation |
|----------------------------|-----|-------|---------------|
| Age                        | 75  | 45.95 | 10.13         |
| ALT [IU/l]                 | 75  | 60.36 | 80.88         |
| AST [IU/l]                 | 75  | 45.02 | 65.73         |
| GGT [IU/l]                 | 75  | 32.69 | 40.69         |
| ALP [IU/l]                 | 75  | 85.22 | 42.20         |
| Total bilirubin [mg/dl]    | 75  | 0.73  | 0.44          |
| Direct bilirubin [mg/dl]   | 75  | 0.29  | 0.22          |
| Total protein [g/dl]       | 74  | 7.26  | 0.57          |
| Albumin [g/dl]             | 74  | 4.23  | 0.37          |
| Haemoglobin [g/dl]         | 74  | 13.97 | 1.74          |
| Leukocytosis [*10^9/μl]    | 75  | 7.20  | 2.43          |
| Platelet [*10^9/μl]        | 75  | 227.04| 55.40         |
| AFP                        | 75  | 2.03  | 1.44          |
| INR                        | 75  | 1.86  | 1.22          |
| HbsAg                      | 75  | 2292.60| 2146.456     |
| HBV-DNA                    | 75  | 1.45 × 10^8| 5.40 × 10^8 |
| HAI score                  | 75  | 4.87  | 2.04          |
| Severity of fibrosis       | 75  | 1.12  | 0.96          |

Table III. Comparison of survivin immunoreactivity and severity of survivin immunoreactivity between chronic hepatitis B patients and controls

| Variable                        | Groups                  | P-value |
|---------------------------------|-------------------------|---------|
|                                 | CHB                     | Control |         |
|                                 | n  | %    | n  | %    |         |
| Survivin immunoreactivity       | Presence                | 46  | 61.3 | 1  | 12.5  | 0.008*  |
|                                | Absence                 | 29  | 38.7 | 7  | 87.5  |         |
| Severity of survivin immunoreactivity | Below 20% | 32  | 42.7 | 1  | 12.5  | 0.028*  |
|                                  | Above 20%               | 14  | 18.7 | 0  | 0.0   |         |

*Significant at 0.05 level; χ² test.

Discussion

Chronic hepatitis B is a well-known pre-malignant condition. In chronic hepatitis phase and cirrhotic phase, affected liver tends to develop HCC. In the literature many studies with variable results have investigated this tendency. These studies mainly focus on mutations and intracellular cascades, which can lead to malignancy. Survivin expression has not been investigated widely in CHB patients. In this study, we are the first according to the literature to show expression of survivin in the liver of CHB patients.

Chronic hepatitis B leads carcinogenesis in many ways, and chronic inflammation is one of them. Chronic inflammation concomitantly increases oxidative stress and radical oxygen species (ROS). It is well known that ROS causes DNA damage, which is a contributor of HCC development. HBV genome insertion to the host DNA
makes hepatocytes more vulnerable to various mutations including tumour suppressor genes [13]. Overall, HbxAg is the key factor and plays a central role in the development of HCC. HBV genome encodes four overlapping open reading frames (ORF), of which X ORF is one [14]. X ORF encodes a 16.5 kDa protein, HbxAg, which has multiple functions. This protein contributes to chronic hepatitis and plays a role in the development of hepatocarcinogenesis in many possible ways [15]. One possible mechanism is activating transcription; Hbx protein elevates the levels of phosphorylated Raf and GTP-bound Ras, which eventually leads to HCC [16]. Hu et al. demonstrated that Hbx protein increases cell proliferation via lncRNA UCA1 [17]. Survivin protein is another important target of Hbx protein on the way to hepatocarcinogenesis. Zhang et al. revealed that Hbx protein accelerates survivin expression in HCC [18]. So, it is possible to conclude that Hbx protein and survivin have an interaction under the circumstances of malignancy, and this interaction may sprout in the chronic hepatitis phase, when we look at our results. But this speculation needs to be confirmed with studies that investigate Hbx protein-survivin interaction in the CHB phase.

Survivin expression in HCC is well documented, and its role is almost completely understood. First of all, survivin inhibits apoptosis in HCC with many ways. Inhibiting caspase activity and binding to hepatitis B X-interacting protein leads its anti-apoptotic effect [18]. Beyond its anti-apoptotic effect, surviving can induce HCC cell proliferation [19]. Also, its expression gains radiotherapy and drug resistance to HCC. Overall its expression negatively affects HCC prognosis. Its crucial role in HCC development and progression makes it an important therapeutic target. Experts concluded that inhibiting surviving can inhibit HCC development and/or progression. Therefore, in vitro and animal studies were performed to investigate molecules that can inhibit the survivin effect [20].

In the course of HCC development, we do not really know when survivin expression starts; in dysplastic nodules, in mature HCC tissue, or in advanced fibrosis? Here we demonstrated that survivin was expressed in the liver of CHB patients. In contrast to our results, Ito et al. showed that 8 patients with cirrhosis and chronic hepatitis did not express survivin [12]. Nonetheless they did not give any information about their causes of these

| Table IV. Comparison of HAI, presence of fibrosis, and bridging fibrosis according to survivin immunoreactivity |

| Parameter          | Survivin immunoreactivity |   |   | P-value |
|--------------------|---------------------------|---|---|---------|
|                    | Presence | % | Absence | % |         |
| HAI                |          |   |          |   |         |
| Minimal            | 15       | 32.6 | 8        | 27.6 | 0.725   |
| Mild               | 28       | 60.9 | 20       | 69.0 |         |
| Moderate           | 3        | 6.5  | 1        | 3.4  |         |
| Fibrosis           |          |   |          |   |         |
| Presence           | 31       | 67.4 | 21       | 72.4 | 0.646   |
| Bridging fibrosis  | Presence | 5  | 10.9     | 0   | 0.066   |

*Significant at 0.05 level; χ² test.

| Table V. Comparison of HAI, presence of fibrosis, and bridging fibrosis according to survivin immunoreactivity severity |

| Parameter          | Severity of survivin immunoreactivity |   |   | P-value |
|--------------------|---------------------------------------|---|---|---------|
|                    | Absence | % | Below 20% | % | Above 20% | % |         |
| HAI                |          |   |          |   |          |   |         |
| Minimal            | 8        | 27.6 | 9        | 28.1 | 6        | 42.9 | 0.561   |
| Mild               | 20       | 69.0 | 20       | 62.5 | 8        | 57.1 |         |
| Moderate           | 1        | 3.4  | 3        | 9.4  | 0        | 0.0  |         |
| Fibrosis           |          |   |          |   |          |   |         |
| Presence           | 21       | 72.4 | 22       | 68.8 | 9        | 64.3 | 0.860   |
| Bridging fibrosis  | Presence | 0  | 0.0      | 5   | 15.6     | 0  | 0.027*  |

*Significant at 0.05 level; χ² test.
8 patients. It is important to understand and demonstrate survivin expression in both chronic hepatitis and cirrhotic phases of CHB infection in terms of understanding HCC development and possible drug therapies.

Our study has some limitations. Although immunohistochemistry studies are valuable, immunoblotting and cell culture-based studies are more effective for the investigation of molecules at tissue level. For this reason, our results need to be confirmed by these methods. The retrospective design is another limitation. We did not have any information about the patients’ follow-up and HCC occurrence. In addition, our control group was small because it is hard to find liver tissue without inflammation or chronic damage. It is well known that survivin expression is a poor prognostic factor in HCC, but its prognostic role needs to be evaluated in CHB patients. Despite these limitations, we hope that our study will trigger new studies to clarify this issue.

Acknowledgments
We would like to thank Meral Akdogan Kayhan for encouragement in terms of studies associated with liver and HBV.

Conflict of interest
The authors declare no conflict of interest.

References
1. Ginzberg D, Wong RJ, Gish R. Global HBV burden: guesstimates and facts. Hepatol Int 2018; 12: 315-29.
2. Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol 2015; 87: 1989-99.
3. Mittal S, Kramer JR, Omino R, et al. Role of age and race in the risk of hepatocellular carcinoma in veterans with hepatitis B virus infection. Clin Gastroenterol Hepatol 2018; 16: 252-9.
4. Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol 2016; 65: 1148-54.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
6. Chiou SK, Jones MK, Tarnawski AS. Survivin – an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 2003; 9: P25-9.
7. Escuín D, Rosell R. The anti-apoptosis survivin gene and its role in human cancer: an overview. Curr Lung Cancer 1999; 1: 138-43.
8. Adida C, Crotty PL, Mcgrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152: 43-9.
9. Jiang X, Wilford C, Duensing S, et al. Participation of survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J Cell Biochem 2001; 83: 342-54.
10. Gunalid M, Isiksacan N, Kocoglu H, et al. The value of serum survivin level in early diagnosis of cancer. J Cancer Res Ther 2018; 14: 570-3.
11. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the apoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-3.
12. Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080-5.
13. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723-50.
14. Ciepe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018; 285: 38-54.
15. Feitelson MA, Reis HM, Liu J, et al. Hepatitis B virus X antigen (HBxag) and cell cycle control in chronic infection and hepatocarcinogenesis. Front Biosci 2005; 10: 1558-72.
16. Gearhart TL, Bouchard MJ. The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol 2010; 84: 2675-86.
17. Hu JJ, Song W, Zhang SD, et al. HBx upregulated IncRNA UCA1 promotes cell growth and tumorigenesis by recruiting EZH2 and repressing p27Kip1/CDK2 signaling. Sci Rep 2016; 6: 23521.
18. Zhang W, Lu Z, Kong G, et al. Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP. Mol Cancer 2014; 13: 128.
19. Singh N, Krishnakumar S, Kanwar RK, et al. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov Today 2015; 20: 578-87.
20. Carrasco RA, Stamm NB, Marcussen E, et al. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 2011; 10: 221-32.

Received: 19.06.2019
Accepted: 15.07.2019